NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high …
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high …
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical ne…
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical nee…
Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical …
Sorbitol correlates with disease severity in patients with SORD Deficiency AT-007 treatment substantially reduced sorbitol levels in a pilot study in SORD Deficiency Sorbitol elevation results in mitochondrial dysfunction, neuronal loss, and climbing d…
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical n…
NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical n…
Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022 NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmac…
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical n…
©2020 Applied Therapeutics All Rights Reserved
©2020 Applied Therapeutics All Rights Reserved